BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+13.81%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.53B
AUM Growth
+$567M
(+8.1%)
Cap. Flow
-$9.29M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13
Top Buys
| 1 |
Incyte
INCY
|
$17.1M |
| 2 |
Intuitive Surgical
ISRG
|
$15.7M |
| 3 |
DexCom
DXCM
|
$14.5M |
| 4 |
Centene
CNC
|
$13.5M |
| 5 |
Abbott
ABT
|
$12.6M |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
$40.9M |
| 2 |
UnitedHealth
UNH
|
$38.4M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$32.9M |
| 4 |
Elevance Health
ELV
|
$27.2M |
| 5 |
Molina Healthcare
MOH
|
$18M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Industrials | 0.38% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Omnicell
OMCL
$1.51B
| $26.1M | 0.35% |
518,384
+104,100
| +25% | +$5.25M |
|
77
Mersana Therapeutics
MRSN
$34.2M
| $25.1M | 0.33% |
171,304
+8,000
| +5% | +$1.17M |
|
78
Adaptive Biotechnologies
ADPT
$1.92B
| $22.6M | 0.3% |
2,960,131
-319,489
| -10% | -$2.44M |
|
79
Castle Biosciences
CSTL
$661M
| $22.2M | 0.3% |
944,312
+2,441
| +0.3% | +$57.5K |
|
80
Phreesia
PHR
$1.79B
| $21.6M | 0.29% |
666,419
| – | – |
|
81
Kezar Life Sciences
KZR
$28.3M
| $21.3M | 0.28% |
303,100
| – | – |
|
82
Privia Health
PRVA
$2.82B
| $20.5M | 0.27% |
900,666
+385,636
| +75% | +$8.76M |
|
83
ResMed
RMD
$39.6B
| $20.5M | 0.27% |
98,275
+13,663
| +16% | +$2.84M |
|
84
ESSA Pharma
EPIX
$11.1M
| $19.9M | 0.26% |
7,898,583
+2,000,000
| +34% | +$5.04M |
|
85
Scholar Rock
SRRK
$3.13B
| $19.5M | 0.26% |
2,152,025
| – | – |
|
86
Illumina
ILMN
$15B
| $19.2M | 0.25% |
97,564
+9,231
| +10% | +$1.82M |
|
87
CVS Health
CVS
$93.2B
| $19M | 0.25% |
204,205
-20,909
| -9% | -$1.95M |
|
88
Hologic
HOLX
$14.6B
| $18.2M | 0.24% |
243,171
-8,241
| -3% | -$617K |
|
89
Legend Biotech
LEGN
$6.46B
| $17.7M | 0.24% |
354,789
-270,672
| -43% | -$13.5M |
|
90
Align Technology
ALGN
$9.58B
| $16.7M | 0.22% |
79,194
+4,255
| +6% | +$897K |
|
91
Baxter International
BAX
$12.1B
| $16.3M | 0.22% |
320,681
+1,133
| +0.4% | +$57.7K |
|
92
Doximity
DOCS
$12.6B
| $15.1M | 0.2% |
448,579
+255,140
| +132% | +$8.56M |
|
93
Generation Bio
GBIO
$40.2M
| $14.3M | 0.19% |
362,728
| – | – |
|
94
10x Genomics
TXG
$1.64B
| $11.8M | 0.16% |
324,746
+70,612
| +28% | +$2.57M |
|
95
Regeneron Pharmaceuticals
REGN
$60.8B
| $11.3M | 0.15% |
15,678
-1,711
| -10% | -$1.23M |
|
96
Gilead Sciences
GILD
$141B
| $11.2M | 0.15% |
130,343
+32,489
| +33% | +$2.79M |
|
|
NVRO
97
DELISTED
NEVRO CORP.
NVRO
| $10.3M | 0.14% |
260,835
| – | – |
|
98
Amgen
AMGN
$152B
| $10.2M | 0.14% |
38,939
-6,257
| -14% | -$1.64M |
|
99
Avantor
AVTR
$8.74B
| $9.95M | 0.13% |
471,621
-31,386
| -6% | -$662K |
|
100
Black Diamond Therapeutics
BDTX
$162M
| $9.72M | 0.13% |
5,400,839
+683,726
| +14% | +$1.23M |
|